Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Maintenance for High-Risk B-ALL Post-Allo-HSCT
NCT06658938Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
Open-label, single-arm trial of blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Cumulative Incidence of Relapse at 2 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06658938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658938.